Nicolas Poirier

Nicolas Poirier

Company: OSE Immunotherapeutics

Job title: Chief Executive Officer

Seminars:

Roundtables: Exploring Novel Technologies From Discovery Through to the Clinic to Ensure Success of Your Molecule 4:30 pm

Using predictive computational models to identify treatment responders/non-responders Assessing drug properties and predict pharmacokinetics, optimize formulations Optimizing clinical trial design Leveraging artificial intelligence to enhance production and manufacturing of your moleculeRead more

day: Conference Day Two

Chair’s Opening Remarks 8:20 am

Read more

day: Conference Day One

Revealing Cytomask®: Cis-Demasking Cytokine Technology for Targeted Delivery 1:30 pm

Outlining masking cytokine technology, allowing activity on-demand at the Right Site but suffers from enzyme selectivity Cis-delivery cytokine technology allows redirection of activity on the right cells but requires potent cytokine attenuation and non-optimal cell selectivity Cytomask® is a novel Cis-Demasking cytokine technology avoiding cytokine attenuation and lack of selectivity of cleavable linkers to unmask…Read more

day: Conference Day One

Chair’s Closing Remarks 5:30 pm

Read more

day: Conference Day One

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.